A Rapidly Expanding Global Market Opportunity
By 2026, the global cervical cancer screening and diagnostics market is projected to reach approximately USD 10.3–10.4 billion, driven by expanding national screening programs, increasing awareness of early detection. The market is expected to grow at an estimated 6.3% CAGR in the near term, with North America leading in adoption and reimbursement infrastructure, while Asia-Pacific is emerging as the fastest-growing region due to expanding healthcare access and large underserved populations.
Scalable Global Expansion Across a 1.85 Billion Women Market Opportunity
The total global female population is roughly 4 billion. If we isolate the specific target screening age bracket of 23–64 years old, the total global pool is approximately 1.85 billion women
WHO Global Screening Goal
Primary Source: Cervical cancer elimination initiative
Start with USA and EU, then
Japan, South Korea, Taiwan..
Primary Source: WHO & The World Bank Data
Such as: Southeast Asia, Pakistan, India, Indonesia
Facing Lack of Lab Equipment, or Long Waiting Lists.
Sub-Saharan Africa & parts of Southern Asia
Heavily rely on international organizations
The USHD Platform
with Real Time Telemedicine
Reduce Healthcare Burden Globally
Cervical Cancer Screening and AI-Assisted Diagnosis are Only the Beginning
UltraSightHD is building a globally reimbursed AI-powered cervical cancer screening platform targeting over 685 million women across reimbursed healthcare markets.
| Revenue Stream | Business Model | Strategic Value |
|---|---|---|
| SaaS Platform Licensing | Annual platform subscription licenses for hospitals, clinics, laboratories & healthcare systems | Recurring high-margin software revenue with scalable global deployment |
| AI Assist Diagnostic Fees | Per-screen or per-test AI-assisted diagnostic analysis fees | Expanding recurring transaction-based revenue tied to screening volume |
| Hardware & System Sales | Sales of screening systems, imaging devices, and integrated platform units | Initial deployment revenue and installed base expansion |
| Longitudinal Imaging Database | Large-scale cervical imaging database infrastructure | Proprietary women's health clinical intelligence assets |
| Continuous AI Learning | Ongoing model training and algorithm optimization using expanding clinical datasets | Improves platform performance, competitive moat, and long-term AI value |
| Population Health Analytics | Disease tracking, screening analytics, and public health reporting tools | Potential partnerships with governments, healthcare systems, and NGOs |
| Pharma & Research Partnerships | Data collaborations and research programs with pharmaceutical and clinical organizations | Future high-value strategic partnership and licensing opportunities |
| Global Women's Health Data Infrastructure | Scalable AI-driven screening and data ecosystem | Positions USHD as foundational infrastructure for women's health AI worldwide |
From early Detection to Global Eradication.
Own the infrastructure. Capture the recurring revenue. Solve the crisis.